Second-generation FASN inhibitors—TVB-3664, TVB-3166, and TVB-2640—exhibit potent antitumor activity in vitro and in vivo and are currently undergoing clinical evaluation in CRC patients (107). The gene discussed is FASN; the disease is colorectal carcinoma.